- ● known allergy or hypersensitivity to the used medications - known severe liver disease (e.g., cirrhosis, with an alanine aminotransferase level >5× the upper limit of the normal range or an aspartate aminotransferase level >5× the upper limit of the normal range) - use of medications that are contraindicated with the trial medications and that could not be replaced or stopped during the trial period - pregnancy or breast-feeding or known active hcv infection, because of concerns about the development of resistance - history of bone marrow transplant - known g6pd deficiency - chronic hemodialysis or glomerular filtration rate < 20ml/min - psoriasis - porphyria - concomitant use of digitalis, flecainide, amiodarone, procainamide, or propafenone - known history of long qt syndrome - current known qtc>500 msec - pregnant or nursing - weight < 35kg - seizure disorder - patients receiving amiodarone.

- ● known allergy or hypersensitivity to the used medications - known severe liver disease (e.g., cirrhosis, with an alanine aminotransferase level >5× the upper limit of the normal range or an aspartate aminotransferase level >5× the upper limit of the normal range) - use of medications that are contraindicated with the trial medications and that could not be replaced or stopped during the trial period - pregnancy or breast-feeding or known active hcv infection, because of concerns about the development of resistance - history of bone marrow transplant - known g6pd deficiency - chronic hemodialysis or glomerular filtration rate < 20ml/min - psoriasis - porphyria - concomitant use of digitalis, flecainide, amiodarone, procainamide, or propafenone - known history of long qt syndrome - current known qtc>500 msec - pregnant or nursing - weight < 35kg - seizure disorder - patients receiving amiodarone.